Tier 4 — mechanistic

Neuropharmacological Effects of Quercetin: A Literature-Based Review

Md Shahazul Islam, Cristina Quispe, Rajib Hossain, Muhammad Torequl Islam, Ahmed Al-Harrasi, Ahmed Al-Rawahi, Miquel Martorell, Assem Mamurova, Ainur Seilkhan, Nazgul Altybaeva, Bagila Abdullayeva, Anca Oana Docea, Daniela Calina, Javad Sharifi-Rad
Frontiers in pharmacology 2021 12:665031

Bibliography

PubMed
PMID 34220504
PubMed Central
PMC8248808
DOI
10.3389/fphar.2021.665031
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignNarrative review of neurological mechanisms and experimental studies
ModelNarrative or mixed evidence review
SampleLaboratory, animal, and limited human literature; no new trial cohort
InterventionQuercetin across neurotoxicity and neurodegeneration models
DurationLiterature available at publication
EndpointsInflammatory measures; Oxidative-stress measures; Events and survival

What the study showed, in plain terms

Published in 2021, this source examined brain, cognition and sleep. Its evidence base was Laboratory, animal, and limited human literature; no new trial cohort. It evaluated Quercetin across neurotoxicity and neurodegeneration models across Literature available at publication.

The review proposes antioxidant, inflammatory, and cell-survival pathways relevant to neurological disease.

Broad neuroprotective claims rely heavily on experimental models. It does not establish prevention or treatment of human neurodegenerative disease.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review proposes antioxidant, inflammatory, and cell-survival pathways relevant to neurological disease.
  • The recorded outcome domains were Inflammatory measures; Oxidative-stress measures; Events and survival.

What this study can and cannot tell us

  • Broad neuroprotective claims rely heavily on experimental models. It does not establish prevention or treatment of human neurodegenerative disease.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology